Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Pacific Biosciences of California Inc. (PACB)

5.43   0.09 (1.69%) 12-12 16:00
Open: 5.33 Pre. Close: 5.34
High: 5.47 Low: 5.31
Volume: 908,897 Market Cap: 839M
Pacific Biosciences of California Inc is a biotechnology company. It is engaged in design, development, and manufacture of sequencing system to help scientists resolve genetically complex problems.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.471 - 5.49 5.49 - 5.507
Low: 5.255 - 5.28 5.28 - 5.302
Close: 5.391 - 5.425 5.425 - 5.457

Technical analysis

as of: 2019-12-12 4:33:32 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 6.39     One year: 7.46
Support: Support1: 4.79    Support2: 4.37
Resistance: Resistance1: 5.47    Resistance2: 6.39
Pivot: 5.14
Moving Average: MA(5): 5.18     MA(20): 5.05
MA(100): 5.25     MA(250): 6.31
MACD: MACD(12,26): 0.08     Signal(9): 0.04
Stochastic oscillator: %K(14,3): 78.31     %D(3): 66.99
RSI: RSI(14): 66.17
52-week: High: 7.51  Low: 4.37  Change(%): -27.3
Average Vol(K): 3-Month: 156238  10-Days: 103661

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
PACB has closed above the upper band by 17.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Pacific Biosciences Stock
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Diagnostics Research
Shares Out. (M) 153.03
Shares Float (M) 149.42
% Held by Insiders 4.18
% Held by Institutions 74.12
Shares Short (K) 18740
Shares Short P. Month (K)

Stock Financials

EPS -0.757
Book Value (p.s.) 0.330
PEG Ratio -0.24
Profit Margin -139.22
Operating Margin -116.08
Return on Assets (ttm) -36.4
Return on Equity (ttm) -125.6
Qtrly Rev. Growth 20.7
Gross Profit (p.s.) 0.164
Sales Per Share
EBITDA (p.s.) -0.578
Qtrly Earnings Growth
Operating Cash Flow (M) -79.12
Levered Free Cash Flow (M) -23.60

Stock Valuations

P/E -7.17
P/E Growth Ratio 0.02
P/BV 16.45
P/S 10.05
P/CF -10.50

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.